Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
MDT/SBRT delays progression across oligomet prostate states; ARTO is the first RCT to suggest an OS benefit.
Single-site day. Fonteyne's EAU 2026 review maps the oligomet prostate landscape for RT: ARTO leads with an OS signal in castration-resistant disease; WOLVERINE shows PFS/CRPC delay without OS; de novo HSPC awaits STAMPEDE2. Selection, not lesion count, is the actionable gate.
read the full digest →Studies · 73
- EAU 2026: MDT/SBRT in oligometastatic prostate cancer (Fonteyne review)MDT/SBRT delays progression across oligomet prostate states; only ARTO suggests an OS benefit; de novo HSPC and patient selection remain unsettled.
- NRG Oncology/RTOG 0848OS HR 0.96 (90% CI 0.79-1.18), p=0.77; adding adjuvant chemoradiation to gemcitabine did not improve survival after resected pancreatic head adenoca.
- RAPCHEM (BOOG 2010-03)10-yr LRR 2.9% overall with response-adapted RT de-escalation post-NAC; low across all risk strata.
- NRG Oncology RTOG 053910-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk WHO grade 1-3 meningioma at median ~12yr f/u.
- FIRESTORMDose-escalated postop RT: 5-yr PFS 65.8% vs 38.8%, MVA HR 0.40 (0.24-0.69) in high-risk meningioma.
- PrTK03 (aglatimagene besadenovec + EBRT)DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer.
- AREST3-yr LRFS 89.2% vs 80.9%, HR 0.52 (p=0.02) favoring adj RT in pT1-2 pN0 OSCC with intermediate-risk features; DFS/OS NS.
- mRCAT-IIIpCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC.
- Breast RT + Systemic Therapy Concurrency Review (Speers)T-DXd ILD 9.6% vs T-DM1 1.6% (DESTINY-Breast05); ASCO26 PK-guided concurrency framework for breast RT + systemic agents.
- ES-SCLC Concurrent TRT + Chemoimmunotherapy (LBA8005)mOS 10.0 vs 11.8mo, HR 1.14, p=0.40: concurrent TRT adds no OS benefit to chemoIO in ES-SCLC.
- ctDNA surveillance in non-operative rectal cancer managementctDNA sensitivity only 41% for local regrowth vs 74% for distant mets in 110 NOM rectal pts; risk stratifies but cannot replace imaging.
- DeLLphi-304 (tarlatamab CNS outcomes)CNS PFS HR 0.54 (ITT), HR 0.40 in brain mets; CNS CR 14.9% vs 5.4% with tarlatamab vs chemo 2L SCLC.